Immune checkpoint inhibitors in challenging populations
Open accessAbstract
Immune checkpoint inhibitors, including those targeting the programmed cell death 1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice have not qualified for or have been seriously underrepresented in immune checkpoint inhibitor clinical trials. Thus, a major gap in knowledge regarding the safety and efficacy of these agents persists in many populations, even after regulatory approval. To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical populations to assist both academic and community oncologists in treatment decision making. Specifically, this review focuses on the safety and activity of immune checkpoint inhibitors in patients with autoimmune disorders, organ transplant patients, patients with chronic viral infections, patients with ongoing immunosuppressant use, patients with organ dysfunction, pregnant patients, patients with brain metastases, patients at extremes of age, and patients with an impaired functional status. Cancer 2017;123:1904-1911. © 2017 American Cancer Society.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The safety and effectiveness of immune-checkpoint inhibitor therapy in solid organ transplantation recipients are unknown.
“Thus, the safety and effectiveness of ICI therapy in this special population are unknown.34”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398 · see citing works
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680 · see citing works
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · see citing works
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · see citing works
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,580 · see citing works
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565 · see citing works
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · see citing works
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091 · see citing works
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069 · see citing works
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
Lewis, J. H., Kilgore, M. L., Goldman, D. P., Trimble, E. L., Kaplan, R. S., Montello, M. J., Housman, M. G., & Escarce, J. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.010 · Cited by 1,029 · see citing works
Goldberg, S. B., Gettinger, S. N., Mahajan, A. K., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J. V., Vortmeyer, A. O., Jilaveanu, L. B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30053-5 · Cited by 994 · see citing works
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817 · see citing works
Prokunina‐Olsson, L., Castillejo-López, C., Oberg, F. G., Gunnarsson, I., Berg, L., Magnusson, V., Brookes, A. J., Tentler, D., Kristjansdóttir, H., Gröndal, G., et al. (2002) · Nature Genetics · doi:10.1038/ng1020 · Cited by 770 · see citing works
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson, H. G., Bao, Y., Shah, M. A., Paulk, M. E., LeBlanc, T. W., Schneider, B. J., Garrido, M. M., Reid, M. C., Berlin, D., Adelson, K. B., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2378 · Cited by 648 · see citing works
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · see citing works
Self-citationIpilimumab for Patients with Relapse after Allogeneic Transplantation
Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C. L., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y., McSweeney, P. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 595 · see citing works
Prognostic Factors for Survival in Patients With Inoperable Lung Cancer 2
Stanley, K. (1980) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/65.1.25 · Cited by 564 · see citing works
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511 · see citing works
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481 · see citing works
Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S., Morris, L., Holland, H., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168468 · Cited by 343 · see citing works
Wright, A. A., Zhang, B., Keating, N. L., Weeks, J. C., & Prigerson, H. G. (2014) · BMJ · doi:10.1136/bmj.g1219 · Cited by 340 · see citing works
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331 · see citing works
Nishijima, T. F., Muss, H. B., Shachar, S. S., & Moschos, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.006 · Cited by 293 · see citing works
Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
Lipson, E. J., Bagnasco, S. M., Moore, J. D., Jang, S., Patel, M. J., Zachary, A. A., Pardoll, D. M., Taube, J. M., & Drake, C. G. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509268 · Cited by 278 · see citing works
Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A. S., Harrison, L. B., Caudell, J. J., Yu, H., Etame, A. B., Weber, J. S., & Gibney, G. T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv622 · Cited by 239 · see citing works
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Klocke, K., Sakaguchi, S., Holmdahl, R., & Wing, K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603892113 · Cited by 232 · see citing works
Hadji, P., Coleman, R., Wilson, C., Powles, T. J., Clézardin, P., Aapro, M., Costa, L., Body, J., Markopoulos, C. J., Santini, D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv617 · Cited by 208 · see citing works
Tanaka, K., Albin, M. J., Yuan, X., Yamaura, K., Habicht, A., Murayama, T., Grimm, M. R., Waaga, A. M., Ueno, T., Padera, R. F., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5204 · Cited by 207 · see citing works
El-Khoueiry, A. B., Melero, I., Crocenzi, T. S., Welling, T. H., Yau, T. C., Yeo, W., Chopra, A., Grosso, J. F., Lang, L., Anderson, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba101 · Cited by 195 · see citing works
Mould, D. R., & Sweeney, K. (2007) · PubMed · Cited by 172 · see citing works
The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance
D’Addio, F., Riella, L. V., Mfarrej, B. G., Chabtini, L., Adams, L. T., Yeung, M. Y., Yagita∥, H., Azuma, M., Sayegh, M. H., & Guleria, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002031 · Cited by 172 · see citing works
Prevalence of Autoimmune Disease Among Patients With Lung Cancer
Khan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2238 · Cited by 162 · see citing works
Lipson, E. J., Bodell, M. A., Kraus, E. S., & Sharfman, W. H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2314 · Cited by 158 · see citing works
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A. J., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A. D., Wang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214788 · Cited by 152 · see citing works
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
Spain, L. A., Higgins, R. M., Gopalakrishnan, K., Turajlic, S., Gore, M. E., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw130 · Cited by 145 · see citing works
Wolchok, J. D. (2015) · Cell · doi:10.1016/j.cell.2015.07.045 · Cited by 139 · see citing works
Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
Morales, R. E., Shoushtari, A. N., Walsh, M. M., Grewal, P., Lipson, E. J., & Carvajal, R. D. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0066-0 · Cited by 110 · see citing works
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
Davar, D., Wilson, M. A., Pruckner, C., & Kirkwood, J. M. (2015) · Case Reports in Oncological Medicine · doi:10.1155/2015/737389 · Cited by 103 · see citing works
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
Herz, S., Höfer, T., Papapanagiotou, M., Leyh, J., Meyenburg, S., Schadendorf, D., Ugurel, S., Roesch, A., Livingstone, E., Schilling, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.026 · Cited by 102 · see citing works
Poulet, F. M., Wolf, J. J., Herzyk, D. J., & DeGeorge, J. J. (2016) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.21176 · Cited by 97 · see citing works
Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma
Ranganath, H., & Panella, T. J. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000077 · Cited by 94 · see citing works
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
Saha, A., O’Connor, R. S., Thangavelu, G., Lovitch, S. B., Dandamudi, D. B., Wilson, C. B., Vincent, B. G., Tkachev, V., Pawlicki, J. M., Furlan, S. N., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85796 · Cited by 91 · see citing works
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers
Aoki, T., Hino, M., Koh, K., Kyushiki, M., Kishimoto, H., Arakawa, Y., Hanada, R., Kawashima, H., Kurihara, J., Shimojo, N., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26018 · Cited by 90 · see citing works
Shi, X., Mancham, S., Hansen, B. E., de Knegt, R. J., de Jonge, J., van der Laan, L. J. W., Rivadeneira, F., Metselaar, H. J., & Kwekkeboom, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.034 · Cited by 86 · see citing works
Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy
Boils, C. L., Aljadir, D., & Cantafio, A. W. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13786 · Cited by 82 · see citing works
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Ong, M., Ibrahim, A. M., Bourassa‐Blanchette, S., Canil, C., Fairhead, T., & Knoll, G. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0171-8 · Cited by 81 · see citing works
Systemic Immunotherapy for the Treatment of Brain Metastases
Cohen, J. V., & Kluger, H. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00049 · Cited by 78 · see citing works
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0166-5 · Cited by 75 · see citing works
Self-citationFatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma
Singh, A. K., Porrata, L. F., Aljitawi, O. S., Lin, T. L., Shune, L. O., Ganguly, S., McGuirk, J. P., & Abhyankar, S. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.111 · Cited by 72 · see citing works
Lukens, J. R., Cruise, M. W., Lassen, M. G., & Hahn, Y. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4875 · Cited by 62 · see citing works
Owonikoko, T. K., Kumar, M., Yang, S., Kamphorst, A. O., Pillai, R. N., Akondy, R. S., Nautiyal, V., Chatwal, M. S., Book, W., Sahu, A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1918-2 · Cited by 59 · see citing works
Yared, J. A., Hardy, N. M., Singh, Z. N., Hajj, S., Badros, A. Z., Kocoglu, M. H., Yanovich, S., Sausville, E. A., Ujjani, C. S., Ruehle, K., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.346 · Cited by 56 · see citing works
Villasboas, J. C., Ansell, S. M., & Witzig, T. E. (2016) · Oncotarget · doi:10.18632/oncotarget.7177 · Cited by 55 · see citing works
Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation
Angenendt, L., Schliemann, C., Lutz, M., Rebber, E., Schulze, A. B., Weckesser, M., Stegger, L., Schäfers, M. A., Groth, C., Keßler, T., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.266 · Cited by 54 · see citing works
José, A. D. L. F. H., Yiannoullou, P., Bhutani, S., Denley, H., Morton, M., Picton, M. L., Summers, A., van Dellen, D., & Augustine, T. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2016.07.019 · Cited by 53 · see citing works
Salloum, R. G., Smith, T. J., Jensen, G. A., & Lafata, J. E. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.019 · Cited by 51 · see citing works
Possible Interaction of Anti–PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases
Alomari, A. K., Cohen, J. V., Vortmeyer, A. O., Chiang, A. C., Gettinger, S. N., Goldberg, S. B., Kluger, H. M., & Chiang, V. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0238 · Cited by 51 · see citing works
Chan, T. S. Y., Khong, P., & Kwong, Y. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2764-1 · Cited by 51 · see citing works
Jeong, H.-Y., Lee, Y.-J., Seo, S., Lee, S.-W., Park, S. J., Lee, J.-N., Sohn, H., Yao, S., Chen, L., & Choi, I. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0307168 · Cited by 48 · see citing works
Ring, E. K., Markert, J. M., Gillespie, G. Y., & Friedman, G. K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1829 · Cited by 45 · see citing works
Responses to immune checkpoint inhibitors in nonagenarians
Johnpulle, R. A. N., Conry, R. M., Sosman, J. A., Puzanov, I. J., & Johnson, D. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1234572 · Cited by 27 · see citing works
Shad, A. T., Huo, J. S., Darcy, C. T., Abu‐Ghosh, A., Esposito, G., Holuba, M. J., Robey, N. C., Cooke, K. R., Symons, H. J., Chen, A. R., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26257 · Cited by 22 · see citing works
Schade, H. H., Sen, S., Neff, C. P., Freed, B. M., Gao, D., Gutman, J. A., & Palmer, B. E. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.007 · Cited by 19 · see citing works
Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma
Rai, R., McQuade, J. L., Wang, D. Y., Park, J., Nahar, K. J., Sosman, J. A., Beckermann, K. E., Haydu, L. E., Lo, S., Rubinstein, S. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw379.08 · Cited by 15 · see citing works
Forconi, C. S., Gatault, P., Miquelestorena‐Standley, E., Noble, J., Al-Hajj, S., Guillemain, R., Stern, M., Hoffmann, T., Prat, L., Suberbielle, C., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.08.014 · Cited by 14 · see citing works
A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis
Dagogo‐Jack, I., Lanfranchi, M., Gainor, J. F., Giobbie‐Hurder, A., Lawrence, D. P., Shaw, A. T., & Sullivan, R. J. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000159 · Cited by 13 · see citing works
Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation
Kwong, Y. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2651-9 · Cited by 12 · see citing works
Aslan, A., Aras, T., & Özdemir, E. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1213835 · Cited by 11 · see citing works
小児T細胞充足,ハプロタイプ一致骨髄移植後のnivolumabの忍容性と有効性:症例報告【Powered by NICT】
Aziza, T. S., Jeffrey, S., Darcy, C. T., Abu‐Ghosh, A., Esposito, G., Holuba, M. J., Robey, N. C., Kenneth, R. C., Heather, J. S., Allen, R., et al. (2017) · Pediatric Blood & Cancer · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,447 · see citing works
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 740 · see citing works
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 753 · see citing works
Drobni, Z. D., Alvi, R. M., Taron, J., Zafar, A., Murphy, S., Rambarat, P. K., Mosarla, R. C., Lee, C., Zlotoff, D. A., Raghu, V. K., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049981 · Cited by 581 · see citing works
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D., Wu, X., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 518 · see citing works
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 452 · see citing works
The integration of inflammaging in age-related diseases
Fülöp, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 356 · see citing works
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, É., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41068 · Cited by 313 · see citing works
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 301 · see citing works
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247 · see citing works
Rheumatic immune-related adverse events from cancer immunotherapy
Calabrese, L. H., Calabrese, C. M., & Cappelli, L. C. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0074-9 · Cited by 233 · see citing works
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 226 · see citing works
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217 · see citing works
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 196 · see citing works
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.274 · Cited by 178 · see citing works
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
Warner, B. M., Baer, A. N., Lipson, E. J., Allen, C. T., Hinrichs, C. S., Rajan, A., Pelayo, E., Beach, M. E., Gulley, J. L., Madan, R. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0823 · Cited by 180 · see citing works
Cancer During Pregnancy: The Oncologist Overview
Hepner, A., Negrini, D., Hase, E. A., Exman, P., Testa, L., Trinconi, Â. F., Filassi, J. R., Francisco, R. P. V., Zugaib, M., O’Connor, T. L., et al. (2019) · World Journal of Oncology · doi:10.14740/wjon1177 · Cited by 157 · see citing works
Fisher, J., Zeitouni, N. C., Fan, W., & Samie, F. H. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.005 · Cited by 157 · see citing works
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
Pérez-De-Lis, M., Retamozo, S., Flores-Chávez, A., Kostov, B., Pérez-Álvarez, R., Brito‐Zerón, P., & Ramos‐Casals, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1372421 · Cited by 149 · see citing works
Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress
Shields, M. D., Marin-Acevedo, J. A., & Pellini, B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321483 · Cited by 141 · see citing works
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136 · see citing works
Sternberg, C. N., Loriot, Y., James, N. D., Choy, E., Castellano, D., López‐Ríos, F., Banna, G. L., Giorgi, U. D., Masini, C., Bamias, A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.015 · Cited by 133 · see citing works
Systemic treatment of HCC in special populations
Rimassa, L., Personeni, N., Czauderna, C., Foerster, F., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.026 · Cited by 132 · see citing works
Renal toxicities associated with pembrolizumab
Izzedine, H., Mathian, A., Champiat, S., Picard, C., Mateus, C., Routier, É., Varga, A., Malka, D., Leary, A. F., Michels, J., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy100 · Cited by 131 · see citing works
Immune Checkpoint Inhibitor Toxicity
Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 123 · see citing works
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Kaufman, H. L., Atkins, M. B., Subedi, P., Wu, J. J., Chambers, J. D., Mattingly, T. J., Campbell, J. D., Allen, J., Ferris, A. E., Schilsky, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0594-0 · Cited by 110 · see citing works
Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 101 · see citing works
Immune Checkpoint Molecules in Reproductive Immunology
Mikó, É., Meggyes, M., Doba, K., Barakonyi, A., & Szereday, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00846 · Cited by 99 · see citing works
Gynecologic cancer in pregnancy
Korenaga, T.-R. K., & Tewari, K. S. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.03.015 · Cited by 97 · see citing works
Managing cardiotoxicity associated with immune checkpoint inhibitors
Upadhrasta, S., Elias, H., Patel, K., & Zheng, L. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.02.004 · Cited by 82 · see citing works
Da, L., Teng, Y., Wang, N., Zaguirre, K., Liu, Y., Qi, Y., & Song, F. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01671 · Cited by 80 · see citing works
Xu, W., Moor, R., Walpole, E. T., & Atkinson, V. G. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000586 · Cited by 79 · see citing works
Jamal, S., Hudson, M., Fifi-Mah, A. V., & Ye, C. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.190084 · Cited by 77 · see citing works
Cacciotti, C., Choi, J. J., Alexandrescu, S., Zimmerman, M. A., Cooney, T. M., Chordas, C. A., Clymer, J. R., Chi, S. N., & Yeo, K. K. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03578-6 · Cited by 79 · see citing works
“How Much Time Do I Have?”: Communicating Prognosis in the Era of Exceptional Responders
LeBlanc, T. W., Temel, J. S., & Helft, P. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201211 · Cited by 74 · see citing works
Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint
Floudas, A., Neto, N. G. B., Marzaioli, V., Murray, K., Moran, B., Monaghan, M. G., Low, C., Mullan, R. H., Rao, N. L., Krishna, V., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.139032 · Cited by 73 · see citing works
Youn, B., Trikalinos, N. A., Mor, V., Wilson, I. B., & Dahabreh, I. J. (2020) · Cancer · doi:10.1002/cncr.32624 · Cited by 73 · see citing works
Ready, N., Audigier-Valette, C., Goldman, J. W., Felip, E., Ciuleanu, T., Campelo, M. R. G., Jao, K., Barlési, F., Bordenave, S., Rijavec, E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006127 · Cited by 75 · see citing works
Hussain, N., Naeem, M., & Pinato, D. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1769398 · Cited by 69 · see citing works
Cardiotoxicity of Immune Therapy
Ganatra, S., Parikh, R. B., & Neilan, T. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.07.008 · Cited by 72 · see citing works
Immune checkpoint inhibitor administration during pregnancy: a case series
Andrikopoulou, A., Korakiti, A.-M., Apostolidou, K., Dimopoulos, M. A., & Zagouri, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100262 · Cited by 69 · see citing works
PD-1 checkpoint inhibition: Toxicities and management
Hahn, A. W., Gill, D. M., Agarwal, N., & Maughan, B. L. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.08.005 · Cited by 67 · see citing works
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Gambichler, T., Reuther, J., Scheel, C., & Becker, J. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001145 · Cited by 67 · see citing works
Nanomedicine-based immunotherapy for central nervous system disorders
Hanif, S., Muhammad, P., Chesworth, R., Rehman, F. U., Qian, R., Zheng, M., & Shi, B. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0429-z · Cited by 68 · see citing works
Cao, R., Yuan, L., Ma, B., Wang, G., & Tian, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01362-0 · Cited by 65 · see citing works
Su, Q., Zhang, X., Zhang, C., Hou, Y., Yao, Y., & Cao, B. (2018) · Journal of Immunology Research · doi:10.1155/2018/1027323 · Cited by 64 · see citing works
Keeping Expectations in Check With Immune Checkpoint Inhibitors
Temel, J. S., Gainor, J. F., Sullivan, R. J., & Greer, J. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2146 · Cited by 62 · see citing works
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 62 · see citing works
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 60 · see citing works
Pregnancy-Associated Breast Cancer: A Diagnostic and Therapeutic Challenge
Galati, F., Magri, V., Arias-Cadena, P. A., Moffa, G., Rizzo, V., Pasculli, M., Botticelli, A., & Pediconi, F. (2023) · Diagnostics · doi:10.3390/diagnostics13040604 · Cited by 58 · see citing works
Wang, S., Chen, C., Li, M., Qian, J., Sun, F., Li, Y., Yu, M., Wang, M., Zang, X., Zhu, R., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1251-0 · Cited by 58 · see citing works
Jeyakumar, N., Etchegaray, M., Henry, J. T., Lelenwa, L. C., Zhao, B., Segura, A., & Buja, L. M. (2020) · Case Reports in Immunology · doi:10.1155/2020/5126717 · Cited by 57 · see citing works
Imaging findings of immune checkpoint inhibitor associated pancreatitis
Das, J. P., Postow, M. A., Friedman, C. F., Do, R. K., & Halpenny, D. F. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109250 · Cited by 57 · see citing works
A light-driven dual-nanotransformer with deep tumor penetration for efficient chemo-immunotherapy
Peng, J., Chen, F., Liu, Y., Zhang, F., Cao, L., You, Q., Yang, D., Chang, Z., Ge, M., Li, L., et al. (2022) · Theranostics · doi:10.7150/thno.68756 · Cited by 58 · see citing works
Cancer and Pregnancy: A Comprehensive Review
Schwab, R. M., Anić, K., & Hasenburg, A. (2021) · Cancers · doi:10.3390/cancers13123048 · Cited by 56 · see citing works
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Seto, T., Sam, D. L., & Pan, M. (2019) · Medical Sciences · doi:10.3390/medsci7020014 · Cited by 51 · see citing works
Heng, W. S., & Cheah, S. (2020) · Molecules · doi:10.3390/molecules25010224 · Cited by 51 · see citing works
Esparvarinha, M., Madadi, S., Aslanian‐Kalkhoran, L., Nickho, H., Dolati, S., Pia, H., Danaii, S., Taghavi, S., & Yousefi, M. (2022) · Cell Biology International · doi:10.1002/cbin.11955 · Cited by 47 · see citing works
Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
Wang, T., Suita, Y., Miriyala, S., Dean, J., Tapinos, N., & Shen, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040520 · Cited by 50 · see citing works
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Yousif, L. I., Screever, E. M., Versluis, D., Aboumsallem, J. P., Nierkens, S., Manintveld, O. C., de Boer, R. A., & Meijers, W. C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01414-4 · Cited by 51 · see citing works
Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 49 · see citing works
Ageing, immune fitness and cancer
Dolan, M., Libby, K. A., Ringel, A. E., van Galen, P., & McAllister, S. S. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00858-z · Cited by 50 · see citing works
Nano-drug delivery systems for T cell-based immunotherapy
Li, R. P., Chen, Z., Li, J., Dai, Z., & Yu, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101621 · Cited by 48 · see citing works
Merkel cell polyomavirus and associated Merkel cell carcinoma
Yang, J. F., & You, J. (2021) · Tumour Virus Research · doi:10.1016/j.tvr.2021.200232 · Cited by 46 · see citing works
T lymphocyte-targeted immune checkpoint modulation in glioma
Kelly, W., Giles, A. J., & Gilbert, M. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000379 · Cited by 46 · see citing works
Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma
Schvartsman, G., Perez, K., Sood, G., Katkhuda, R., & Tawbi, H. A. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0187 · Cited by 45 · see citing works
Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
Zehou, O., Leibler, C., Arnault, J., Sayegh, J., Montaudié, H., Rémy, P., Glotz, D., Cordonnier, C., Martin, L., & Lebbé, C. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15071 · Cited by 45 · see citing works
Immune-Related Adverse Events: A Case-Based Approach
Connolly, C. M., Bambhania, K., & Naidoo, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00530 · Cited by 45 · see citing works
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
Li, L., Li, G., Rao, B., Dong, A.-H., Liang, W., Zhu, J., Qin, M.-P., Huang, W., Lu, J., Li, Z.-F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72649-5 · Cited by 46 · see citing works
Anderson, R., & Rapoport, B. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00080 · Cited by 44 · see citing works
Liang, X., Li, L., Li, X., He, T., Gong, S., Zhu, S., Zhang, M., Wu, Q., & Gong, C. (2021) · Theranostics · doi:10.7150/thno.58173 · Cited by 44 · see citing works
Schadendorf, D., Ascierto, P. A., Haanen, J. B. A. G., Espinosa, E., Демидов, Л. В., Garbe, C., Guida, M., Lorigan, P. C., Chiarion‐Sileni, V., Gogas, H. J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.014 · Cited by 43 · see citing works
Cancer Immunotherapies: Are They as Effective in the Elderly?
Poropatich, K., Fontanarosa, J., Samant, S., Sosman, J., & Zhang, B. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0479-1 · Cited by 39 · see citing works
Balancing Cancer Immunotherapy Efficacy and Toxicity
Johnson, D. B., Jakubovic, B. D., Sibaud, V., & Sise, M. E. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.06.028 · Cited by 43 · see citing works
Immunotherapy use outside clinical trial populations: never say never?
Rzeniewicz, K., Larkin, J., Menzies, A. M., & Turajlic, S. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.199 · Cited by 42 · see citing works
Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis
Yamaguchi, A., Saito, Y., Okamoto, K., Narumi, K., Furugen, A., Takekuma, Y., Sugawara, M., & Kobayashi, M. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06359-7 · Cited by 40 · see citing works
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 39 · see citing works
Bogach, J., Pond, G. R., Eskicioglu, C., & Seow, H. Y. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz088 · Cited by 38 · see citing works
Dow, E., Freimund, A. E., Smith, K. M., Hicks, R. J., Jurcevic, P., Shackleton, M. J., James, P. A., FELLOWES, A. P., Delatycki, M. B., Fawcett, S., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00429 · Cited by 37 · see citing works
Cutaneous immune-related adverse events to checkpoint inhibitors
Malviya, N., Tattersall, I., Leventhal, J. S., & Alloo, A. (2020) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2020.06.011 · Cited by 37 · see citing works
Pantuck, M. A., McDermott, D. F., & Drakaki, A. (2019) · Cancer · doi:10.1002/cncr.32326 · Cited by 37 · see citing works
Majem, M., García-Martínez, E., Martinez, M., Muñoz‐Couselo, E., Rodríguez‐Abreu, D., Álvarez, R., Arance, A. M., Berrocal, A., de la Cruz‐Merino, L., & Lopez-Martin, J. A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02273-x · Cited by 36 · see citing works
Treatment of keratinocyte carcinoma in elderly patients – a review of the current literature
Leus, A. J. G., Frie, M., Haisma, M. S., Terra, J. B., Plaat, B. E. C., Steenbakkers, R. J. H. M., Halmos, G. B., & Rácz, E. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16268 · Cited by 36 · see citing works
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Fan, Y., Geng, Y., Shen, L., & Zhang, Z. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0735-3 · Cited by 35 · see citing works
Chiang, C., Chiang, C., Sheng‐Kai, K., Hsia, Y. P., Lee, Y.-W., Wu, H., Chiang, C., Peng, C.-Y., Wei, J. C., Shiah, H., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac150 · Cited by 36 · see citing works
Xia, Z., Zhang, J., Chen, W., Zhou, H., Du, D., Zhu, K., Chen, H., Meng, J., & Yang, J. (2023) · Infectious Diseases of Poverty · doi:10.1186/s40249-023-01128-6 · Cited by 34 · see citing works
Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, D., Zaheer, S., Sureka, N., Trisal, M., Chaurasia, J. K., & Zaheer, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155864 · Cited by 37 · see citing works
Relapsed Myasthenia Gravis after Nivolumab Treatment
Mitsune, A., Yanagisawa, S., Fukuhara, T., Miyauchi, E., Morita, M., Ono, M., Tojo, Y., & Ichinose, M. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9153-17 · Cited by 34 · see citing works
Delyon, J., Zuber, J., Dorent, R., Poujol‐Robert, A., Péraldi, M., Anglicheau, D., & Lebbé, C. (2020) · Transplantation · doi:10.1097/tp.0000000000003292 · Cited by 34 · see citing works
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
Stege, H. M., Haist, M., Nikfarjam, U., Schultheis, M., Heinz, J., Pemler, S., Loquai, C., & Grabbe, S. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00840-3 · Cited by 35 · see citing works
Yang, W., Li, S., & Yang, Q. (2019) · Medicine · doi:10.1097/md.0000000000015731 · Cited by 33 · see citing works
Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 33 · see citing works
Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches
Motofei, I. G. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0643-4 · Cited by 30 · see citing works
Shannon, V. R., Anderson, R., Blidner, A. G., Choi, J. N., Cooksley, T., Dougan, M. L., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05708-2 · Cited by 29 · see citing works
Chen, H., Li, M., Ng, N., Yu, E., Bujarski, S. E., Yin, Z., Wen, M., Hekmati, T., Field, D., Wang, J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17282 · Cited by 29 · see citing works
Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective
Li, W., Xu, X., & Jin, L. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17022 · Cited by 27 · see citing works
Riaz, I. B., Islam, M., Khan, A. M., Naqvi, S. A. A., Siddiqi, R. L., Khakwani, K. Z. R., Asghar, N., Ikram, W., Hussain, S. A., Singh, P. P., et al. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.03.042 · Cited by 28 · see citing works
Rienzo, M., Skirecki, T., Monneret, G., & Timsit, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2102477 · Cited by 28 · see citing works
- Authors
- Johnson, D. B., Sullivan, R. J., & Menzies, A. M.
- Affiliations
- Vanderbilt University Medical Center (US)
- Massachusetts General Hospital (US)
- The University of Sydney (AU)
- Corresponding author
- Johnson, Douglas B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2017-02-27
- Volume
- 123
- Issue
- 11
- Pages
- 1904-1911
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC5445005
- OpenAlex
- W2592187743
- Cited by
- 339
- References
- 78
- Citations by year
- 2026: 10 · 2025: 30 · 2024: 21 · 2023: 32 · 2022: 42 · 2021: 58 · 2020: 71 · 2019: 42 · 2018: 23 · 2017: 10
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K23 CA204726)
- Cancer Institute NSW
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint inhibitors, PD-1/PD-L1 pathway, underrepresented groups, autoimmune disease, organ transplant recipients, chronic viral infection, immunosuppressants, organ dysfunction, pregnancy, brain metastases, elderly patients, treatment safety, treatment efficacy
- MeSH terms
- Ipilimumab, Squamous Cell Carcinoma of Head and Neck, Nivolumab, Age Factors, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Female, Graft Rejection, Head and Neck Neoplasms, Humans, Immunosuppressive Agents, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pregnancy, Pregnancy Complications, Neoplastic, HIV Infections, Immunocompromised Host, Hepatitis B, Chronic, Hepatitis C, Chronic, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
